Lactulosum Orifarm (Lactulose)

Lactulose reaches the colon unchanged, where intestinal bacteria break it down into short‑chain fatty acids. These acids lower the colonic pH, converting ammonia to ammonium, which is trapped in the lumen and eliminated. The resulting osmotic effect draws water into the bowel, softening stool and stimulating bowel movements.

The appropriate dose of Lactulosum Orifarm is determined by the prescribing healthcare professional based on the individual’s condition, severity, and response to therapy. Dosing may be adjusted over time to achieve the desired clinical effect while minimizing adverse reactions.

Safety data for lactulose in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Lactulose is an osmotic laxative, differing from stimulant laxatives that act on intestinal nerves. It provides a gentler, water‑drawing effect and also lowers ammonia levels, making it useful for hepatic encephalopathy—a benefit not shared by most other laxatives. Its onset may be slower, but it is often preferred when both bowel regularity and ammonia reduction are needed.

Lactulosum Orifarm should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The product is taken orally, usually dissolved in a measured amount of water or other suitable liquid as directed by the prescriber. It can be consumed with or without food, but patients should follow the specific administration instructions provided by their healthcare professional.

Serious risks include severe dehydration, electrolyte imbalances such as hypokalemia, and rare cases of acute colitis or allergic reactions. Patients should be monitored for signs of excessive fluid loss, muscle weakness, or rash, and seek medical attention promptly if these occur.

Lactulose should be avoided in individuals with known hypersensitivity to lactulose or any of its excipients. Caution is also advised for patients with severe renal impairment, intestinal obstruction, or acute abdominal conditions, as the osmotic effect may exacerbate these problems.